Table 1.
Baseline demographic characteristics of patients (N=84) and distribution by site
| Baseline Characteristic | Total N=84 |
VA N=48 |
JHS N=20 |
UHealth N=16 |
|---|---|---|---|---|
| Age, Years (IQR) | 58 (50–66) | 60(47–57) | 57 (60–52) | 54 (61–49) |
| Male, n (%) | 74 (88.1) | 47(97.9) | 15 (75.0) | 12 (75.0) |
| Race | ||||
| Caucasian, n (%) | 28 (33.3) | 15(31.3) | 7 (35.0) | 6 (37.5) |
| Black, n (%) | 42 (50.0) | 28(58.3) | 9 (45.0) | 5 (31.3) |
| Hispanic, n (%) | 14 (16.7) | 5(10.4) | 4 (20.0) | 5 (31.3) |
| HIV RNA <50 IU/ml, Mean (SD) | 76 (90.4) | 44(91.7) | 18 (90.0) | 14 (87.5) |
| Median CD4 count cells/mm3 (IQR) | 604 (812–374) | 570(775–412) | 615 (750–466) | 688 (888–580) |
| HIV Antiviral Regimen | ||||
| Integrase + TDF-FTC, n (%) | 25 (29.8) | 11(22.9) | 4(20.0) | 10(62.5) |
| Integrase+ ABC-3TC, n (%) | 12(14.3) | 7(14.6) | 3(15.0) | 2(12.5) |
| PI/r +, TDF-FTC n (%) | 11 (13.1) | 8(16.7) | 3(15.0) | 0 |
| Rilpivrine+TDF-FTC, n (%) | 5 (6.0) | 0 | 4(20.0) | 1(6.3) |
| EFV+ TDF-FTC, n (%) | 12 (14.4) | 7(14.6) | 3(15.0) | 2(12.5) |
| Others | 19(22.4) | 15(31.2) | 3(15.0) | 1(6.3) |
| HCV genotype- | ||||
| 1a, n (%) | 59 (70.2) | 32(66.7) | 13(65.0) | 14(87.5) |
| 1b, n (%) | 20 (23.8) | 13(27.1) | 6(30.0) | 1(6.3) |
| 2b, n (%) | 3 (3.6) | 2(4.2) | 1(5.0) | 0 |
| Others (3a and 4), n (%) | 2 (2.4) | 1(2.1) | 0 | 1(6.3) |
| Median HCV RNA (IQR), log10IU/ml | 14.9 (12.4–17.4) | 6.4(6.9–5.8) | 6.4(6.6–5.7) | 6.5(7.0–6.3) |
| Cirrhosis, n (%) | 24 (28.6) | 15(31.3) | 6(30.0) | 3(18.8) |
| Prior HCV treatment experienced, n (%) | 49 (58.3) | 25(52.0) | 13(65.0) | 11(68.7) |
| Prior HCV treatment agents | ||||
| PEG IFN/RBV | 30(40.0) | 21(43.8) | 6(33.3) | 3(33.3) |
| Boceprevir/teleprevir | 2(2.7) | 1(2.1) | 1(5.6) | 0 |
| DAAs | 1(1.3) | 1(2.1) | 0 | 0 |
| Other/not known | 8(10.7) | 2(4.2) | 5(27.8) | 1(11.1) |
| Hepatitis B coinfection, n (%) | 13 (15.9) | 8(16.7) | 4(22.2) | 1(6.3) |
| APRI Score, Median (IQR) | 0.57(0.92–0.37) | 0.54(0.75–0.31) | 1.2(2.4–0.6) | 0.48(0.67–0.38) |
| HCV treatment regimen | ||||
| Sofosbuvir+ledipasvir, n (%) | 33 (39.3) | 19(39.6) | 5(25.0) | 9(56.3) |
| Simeprevir+sofosbuvir, n (%) | 25 (29.8) | 10(20.8) | 10(50.0) | 5(31.3) |
| Simeprevir+sofosbuvir+RBV, n (%) | 13(15.5) | 13(27.1) | 0 | 0 |
| Sofosbuvir/IFN/RBV, n (%) | 7 (8.3) | 2(4.2) | 4(20.0) | 1(6.3) |
| Sofosbuvir+RBV, n (%) | 4 (4.8) | 2(4.2) | 1(5.0) | 1(6.3) |
| Ombitasvir+paritaprevir+dasabuvir/r n (%) | 2(2.3) | 2(4.2) | 0 | 0 |
| Concurrent RBV use for HCV treatment, n % | 28(33.7) | 21(43.8) | 5(26.3) | 2(12.5) |
| Attendance to follow up clinic visit, n % | 62(73.8) | 45(93.7) | 6(30.0) | 11(68.7) |
VA: The Miami Veterans Affairs Healthcare System, JHS: Jackson Health System
UHealth: University of Miami Health system
TDF-FTC: Tenofovir-Emtricitabine, ABC-3TC: Abacavir-Lamivudine, PI/r: Ritonavir boosted protease inhibitors, EFV: Efavirenz, APRI: AST to Platelet Ratio Index, /r: Ritonavir, RBV: Ribavirin